What Happened

The FDA reviewed CalciMedica's protocol amendment and interim safety data for the Phase 2 KOURAGE trial of Auxora in AKI patients with AHRF. No comments were provided, allowing dosing to continue. This follows a pause in enrollment due to a mortality imbalance, though no drug-related toxicity was identified.

Who Is Affected

CalciMedica is directly impacted as this decision allows them to proceed with clinical development of Auxora. Biotech companies in the nephrology and cardiology space should monitor this trial's progress as it may influence regulatory expectations for similar therapies.

Market Impact

• CALC stock declined 24.37% following the news, reflecting negative market reaction
• Trading volume surged to 170.1x the average, indicating significant selling pressure
• Approximately $3M was removed from CalciMedica's valuation

What to Watch

Monitor FDA feedback in Q3 2026 on CalciMedica's potential pivotal Auxora program in acute pancreatitis. Additionally, watch for updates on the KOURAGE trial's progress and any further regulatory developments that may impact CalciMedica's valuation or strategic direction.